Abstract：To evaluate the drug-resistance gene mutation of HIV-1 strains in Fujian Province, 226 samples with viral load of HIV-1 in plasma above 1 000 copy/mL were collected from 2008 to 2013. The average of viral load was 1.62×105 copy/mL. Then the whole sequence of gene including the pol gene and the partial reverse transcriptase gene of HIV-1 were amplified by RT-PCR, in which 124 samples were amplified successfully and then the sequences of those amplified ones were edited by the software Conting Express and submitted to the website http//hivdb.stanford.edu./to analyze the drug resistance status. It was found that 92 samples (74.2%) of that strains were classified as CRF_01AE, 14 samples were B, C and BC were 7 samples, respectively. According to the interpretation of Stanford University drug resistance database, 63 of 124 sequences occurred mutations for NRTIs, 74 of 124 sequences occurred mutations for NNRTIs, and 9 of 124 sequences occurred mutations for PIs. The NRTI resistance mutations were M184V, M41L, D67N, L70R, T219F, and K219Q, which caused high or medium level of resistance to TDF, 3TC, D4T and so on. The NNRTI resistance mutations were K101E, Y181C, K103N, and G190A, which caused high or medium level of EFV and NVP. These results showed that the rate of total drug resistance mutation of HIV-1 in Fujian Province was low. But with the increase of the populations using highly active anti-retrovirus therapy and the length of the time during therapy, the mutation may cause high or medium level of drug resistance, so the surveillance for that of HIV-1 is necessary.
[1] Ye S, Feng YL, Ke YF, et al. Analysis of results in antiviral treatment of AIDS patient[J]. China Trop Med, 2006, 30(7): 1143-1144. (in China) 叶晟,冯宇良,柯云峰,等.艾滋病现症病人抗病毒治疗效果分析[J].中国热带医学,2006,30(7):1143-1144. [2] Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV infected infants[J]. N Engl J Med, 2008, 359(21): 2233-2244. doi:10.1056/NEJMoa0800971 [3] Shafer RW. Genotypic testing for human immunodeficiency virus type 1 drug resistance[J]. Clin Microbiol Rev, 2002, 15(2): 247-277. doi:10.1128/CMR.15.2.247-277.2002 [4] Ma Y, Zhang F, Li H, et al. Monitoring HIV drug resistance using early warning indicators in china: results from a pilot survey conducted in 2008[J]. Clin Infect Dis, 2012, 54(S4): S300-S302. doi:10.1093/cid/cir1018 [5] Jiao L, Li H, Li L, et al. Impact of novel resistance profiles in HIV-1 reverse transcriptase on phenotypic resistance to NVP[J]. AIDS Res treat, 2012, 2012(2): 1-8. doi:10.1155/2012/637263 [6] Yan PP, Xie MR, Wu SL, et al. Evaluation of the effectiveness of anti-retroviral therapy on AIDS patients in Fujian province and the current status of their drug resistance pattern[J]. Chin J Zoonoses, 2008, 24(10): 896-900. (in Chinese) 颜苹苹,谢美榕,吴守丽,等.福建省艾滋病患者抗病毒疗效和耐药性检测分析[J].中国人兽共患病学报,2008,24(10):896-900. [7] Tam LW, Hogg RS, Yip B, et al. Performance of a World Health Organization first-line regimen (stavudine/lamivudine) in anti-retroviral-naïve individuals in a Western setting[J]. HIV Med, 2007, 8(5): 267-270.
